Johan Bodegård

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

Mikhail Kosiborod, Matthew A. Cavender, Alex Z. Fu et al. · Circulation · 2017 · 814 citations · Full text

Medicine, Cardiology, Pharmacology +16

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

Carolyn S.P. Lam, Shun Kohsaka, Avraham Karasik et al. · Journal of the American College of Cardiology · 2018 · 466 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Kåre I. Birkeland, Marit E. Jørgensen, Bendix Carstensen et al. · The Lancet Diabetes & Endocrinology · 2017 · 371 citations

Medicine, Internal Medicine, Pharmacotherapy +17

Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study

Johan Sundström, Johan Bodegård, Andreas Bollmann et al. · The Lancet Regional Health - Europe · 2022 · 318 citations · Full text

Medicine, Internal Medicine, Nephrology +17

Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation

Gianluigi Savarese, Takuya Kishi, Orly Vardeny et al. · JACC Heart Failure · 2022 · 284 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16